Close Menu

NEW YORK – PerkinElmer said on Tuesday that it received the CE-IVD mark for its dry blood spot-based test for detecting IgG antibodies against SARS-CoV-2 and has launched it.

The test uses the firm's GSP/Delfia platform, which can process up to 5,000 samples per day. The Waltham, Massachusetts-based company said the finger prick sample collection device allows the test to be used in a decentralized setting as well as in a high-throughput lab.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.